Medically reviewed by Marla Anderson, MD Multiple myeloma is a rare type of blood cancer that forms in plasma cells, a white ...

Bispecific antibody therapy is transforming cancer treatment, especially in multiple myeloma, with ongoing studies exploring early-line and maintenance use.

Arcellx's anito-cel shows promising efficacy and safety in multiple myeloma. Read why I maintain my hold rating for ACLX ...

A team of researchers from the Translational Oncology Research Centre (TORC) of Vrije Universiteit Brussel (VUB), in ...

For patients with relapsed or refractory multiple myeloma, talquetamab plus teclistamab shows response in a high percentage ...

Jodie Hill from Wolverhampton was diagnosed with multiple myeloma in March 2021 which was originally suspected to be diabetes ...

Subcutaneous Sarclisa, administered via OBDS, showed non-inferior efficacy to IV Sarclisa in relapsed/refractory multiple ...

At just 42 years old, Allison Freedman's life took an unexpected and devastating turn. She was a busy mom raising ...

AbbVie and Simcere Zaiming have announced a partnership worth over $1bn to develop an investigational drug candidate for ...

In a retrospective study of 315 patients with relapsed/refractory multiple myeloma, retreatment with previously refractory drugs achieved an overall response rate of 56.2% and median progression-free ...

A team of researchers has developed a new biomaterial with high potential in in the treatment of bone lesions or minimal residual disease in multiple myeloma patients. The findings showcase a ...

2024 was a year of resilience after a myeloma diagnosis, marked by a return to public speaking, a documentary filming ...